Consistent with this view, airway inflammation in CF patients with the G551D mutation was not reduced by the CFTR potentiator VX-770 in spite of improvements in other clinical parameters [64,65], although decreases in airway inflammation were reported in another study [66]. The gene discussed is CFTR; the disease is cystic fibrosis.